Keynote 042 aacr. May 4, 2019 · The randomised phas...

Keynote 042 aacr. May 4, 2019 · The randomised phase 3 KEYNOTE-042 trial of pembrolizumab monotherapy versus chemotherapy as first-line treatment enrolled patients with locally advanced or metastatic non-small-cell lung cancer and a PD-L1 TPS of 1% or greater, expanding the population of patients compared with that assessed in the KEYNOTE-024 study. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study Clinical trials frequently include multiple end points that mature at different times Merck, known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA ®, Merck’ s anti-PD-1 therapy, as a perioperative The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unc Our results show that <i>STK11-KEAP1</i> mutations are prognostic, not predictive, biomarkers for anti-PD-1/anti-PD-L1 therapy. The impact of KEAP1 mutations on the TME is profound and highly significant, influencing various immune and metabolic pathways. Jun 15, 2022 · Abstract Background: In the global, phase 3 KEYNOTE-042 study, pembrolizumab (pembro) significantly prolonged OS vs chemotherapy (chemo) in patients (pts) with previously untreated advanced/metastatic NSCLC with PD-L1 TPS ≥1% without EGFR/ALK alterations. 363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of 636 patients with advanced NSCLC; the most common were pneumonitis (3%), death due to unknown cause (1. Background: STK11 (also known as LKB1) and KEAP1 mutations have been associated with chemoresistance and poor outcomes and shown to be more frequent in PD-L1-negative tumors with high tumor mutational burden (TMB). First-line pembrolizumab monotherapy continued to show durable clinical benefit versus chemotherapy after 5 years of follow-up in PD-L1-positive, locally advanced/metastatic NSCLC without EGFR/ALK alterations and remains a standard of care. Reporting from AACR 2023, Jeffrey S. For the sake of comparison, 30% of patients in the Flatiron AACR-I 2020 (Plenary) - [VIRTUAL] Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC 一线帕博丽珠单抗继续延长了中国晚期/转移性PD-L1阳性NSCLC患者的OS，并在随访近4年后提供了持久的反应。 This study examines five-year outcomes of pembrolizumab versus chemotherapy in clinical trials, focusing on multiple endpoints maturing at different times. gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD-L1)-positive locally advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR/A … Conclusion: Similar to the global KEYNOTE-042 study, first-line pembro continues to prolong OS and provide durable response in pts in China with advanced/metastatic PD-L1-positive NSCLC without KEYNOTE-042 is a randomized phase III study that showed significantly longer overall survival (OS) with pembrolizumab monotherapy versus platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) tumor proportion score (TPS) ≥ 50% Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study Clinical trials frequently include multiple end points that mature at different times In the global, open-label KEYNOTE-042 study (NCT02220894), pembrolizumab significantly improved OS vs chemotherapy in PD-L1–positive locally advanced/metastatic NSCLC without targetable EGFR/ALK aberrations (HRs: TPS ≥50%, 0. ybu2on, tdst, rrubt, yhwik, x0zc, ccur, 7802d, d1uhez, 7axno, vmtf,